The growth in the historic period can be attributed to rising prevalence of type 2 diabetes, expansion of insulin therapy usage, increasing clinical acceptance of combination injectables, growth in endocrinology care access, availability of advanced insulin analogs.
The growth in the forecast period can be attributed to expansion of combination therapy adoption, increasing demand for simplified diabetes treatment regimens, growing focus on weight-neutral glycemic control, rising investments in metabolic disorder treatments, development of next-generation injectable combinations. Major trends in the forecast period include increasing adoption of fixed-ratio combination diabetes therapies, rising preference for once-daily injectable treatments, increasing focus on glycemic control optimization, expansion of glp-1 based combination products, enhanced emphasis on patient adherence.
The increasing prevalence of type 2 diabetes is expected to drive the growth of the Xultophy 100/3.6 market. Type 2 diabetes is a chronic condition marked by insulin resistance and insufficient insulin production, resulting in elevated blood sugar levels. Its rising prevalence is linked to factors such as increasing obesity rates, sedentary lifestyles, poor dietary habits, and genetic predisposition. Xultophy 100/3.6 combines insulin degludec and liraglutide in a single formulation, helping patients achieve better blood sugar control, reduce the number of daily injections, and improve treatment adherence while minimizing risks of hypoglycemia and weight gain. For example, in May 2024, the Centers for Disease Control and Prevention (CDC) reported that over 38 million Americans - about 1 in 10 - have diabetes, with 90% to 95% of cases being type 2 diabetes. Therefore, the rising prevalence of type 2 diabetes is driving the Xultophy 100/3.6 market.
Rising healthcare expenditure is also expected to propel the Xultophy 100/3.6 market. Healthcare expenditure refers to the total spending on healthcare goods and services, including personal care, preventive measures, and public health initiatives aimed at improving overall health outcomes. The increase in expenditure is driven by factors such as an aging population, higher prevalence of chronic diseases, advancements in medical technology, rising drug costs, and greater demand for healthcare services. Higher healthcare spending supports Xultophy 100/3.6 by enabling investments in innovative combination therapies, improving patient access through insurance and subsidy programs, funding awareness campaigns, and facilitating research to optimize treatment outcomes. For instance, in May 2024, a report from the UK Office for National Statistics noted that total healthcare expenditure rose by 5.6% in nominal terms from 2022 to 2023, compared to 0.9% growth in 2022. Therefore, rising healthcare expenditure is boosting the Xultophy 100/3.6 market.
The growing geriatric population is expected to further support the growth of the Xultophy 100/3.6 market. The geriatric population includes individuals aged 65 and older, who often experience age-related health, social, and functional changes. Growth in this population is driven by advancements in healthcare, improved living standards, better nutrition, and increased life expectancy. Xultophy 100/3.6 benefits older adults by offering a convenient and effective treatment option that reduces daily intervention frequency, enhances adherence, minimizes side effects like hypoglycemia, and supports overall health management tailored to older patients. For example, in July 2024, the UK Parliament’s House of Commons Library reported that in 2022, 12.7 million people in the UK were aged 65 or older (19% of the population), projected to rise to 22.1 million (27%) by 2072. Therefore, the expanding geriatric population is driving growth in the Xultophy 100/3.6 market.
Major companies operating in the xultophy 100/3.6 market are Novo Nordisk A/S.
North America was the largest region in the xultophy 100/3.6 market in 2025. The regions covered in the xultophy 100/3.6 market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the xultophy 100/3.6 market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.
Tariffs are impacting the xultophy 100/3.6 market by increasing costs of imported active pharmaceutical ingredients, injectable device components, cold-chain logistics, and sterile packaging materials. North America and Europe are most affected due to dependence on global insulin and GLP-1 supply chains, while Asia-Pacific faces higher import-related costs. These tariffs contribute to increased manufacturing and distribution expenses that may influence pricing and reimbursement. However, they are also encouraging regional production of injectable therapies, localized device assembly, and strengthened domestic pharmaceutical supply chains.
The xultophy 100/3.6 market research report is one of a series of new reports that provides xultophy 100/3.6 market statistics, including xultophy 100/3.6 industry global market size, regional shares, competitors with a xultophy 100/3.6 market share, detailed xultophy 100/3.6 market segments, market trends and opportunities, and any further data you may need to thrive in the xultophy 100/3.6 industry. This xultophy 100/3.6 market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Xultophy 100/3.6 is a combination injectable medication containing 100 units/mL of insulin degludec and 3.6 mg/mL of liraglutide. It is used to manage type 2 diabetes mellitus (T2DM) by improving glycemic control alongside diet and exercise, addressing both insulin deficiency and GLP-1 receptor activity with a convenient once-daily injection.
The main indication for Xultophy 100/3.6 is type 2 diabetes mellitus, a chronic condition in which the body either resists insulin or the pancreas does not produce enough insulin to maintain normal blood glucose levels. It is distributed through hospital pharmacies, retail pharmacies, and online pharmacies, and is used by adult and geriatric patients.
The xultophy 100/3.6 market consists of sales of the prefilled pen for subcutaneous injection and needles. Values in this market are ‘factory gate’ values, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
The growth in the forecast period can be attributed to expansion of combination therapy adoption, increasing demand for simplified diabetes treatment regimens, growing focus on weight-neutral glycemic control, rising investments in metabolic disorder treatments, development of next-generation injectable combinations. Major trends in the forecast period include increasing adoption of fixed-ratio combination diabetes therapies, rising preference for once-daily injectable treatments, increasing focus on glycemic control optimization, expansion of glp-1 based combination products, enhanced emphasis on patient adherence.
The increasing prevalence of type 2 diabetes is expected to drive the growth of the Xultophy 100/3.6 market. Type 2 diabetes is a chronic condition marked by insulin resistance and insufficient insulin production, resulting in elevated blood sugar levels. Its rising prevalence is linked to factors such as increasing obesity rates, sedentary lifestyles, poor dietary habits, and genetic predisposition. Xultophy 100/3.6 combines insulin degludec and liraglutide in a single formulation, helping patients achieve better blood sugar control, reduce the number of daily injections, and improve treatment adherence while minimizing risks of hypoglycemia and weight gain. For example, in May 2024, the Centers for Disease Control and Prevention (CDC) reported that over 38 million Americans - about 1 in 10 - have diabetes, with 90% to 95% of cases being type 2 diabetes. Therefore, the rising prevalence of type 2 diabetes is driving the Xultophy 100/3.6 market.
Rising healthcare expenditure is also expected to propel the Xultophy 100/3.6 market. Healthcare expenditure refers to the total spending on healthcare goods and services, including personal care, preventive measures, and public health initiatives aimed at improving overall health outcomes. The increase in expenditure is driven by factors such as an aging population, higher prevalence of chronic diseases, advancements in medical technology, rising drug costs, and greater demand for healthcare services. Higher healthcare spending supports Xultophy 100/3.6 by enabling investments in innovative combination therapies, improving patient access through insurance and subsidy programs, funding awareness campaigns, and facilitating research to optimize treatment outcomes. For instance, in May 2024, a report from the UK Office for National Statistics noted that total healthcare expenditure rose by 5.6% in nominal terms from 2022 to 2023, compared to 0.9% growth in 2022. Therefore, rising healthcare expenditure is boosting the Xultophy 100/3.6 market.
The growing geriatric population is expected to further support the growth of the Xultophy 100/3.6 market. The geriatric population includes individuals aged 65 and older, who often experience age-related health, social, and functional changes. Growth in this population is driven by advancements in healthcare, improved living standards, better nutrition, and increased life expectancy. Xultophy 100/3.6 benefits older adults by offering a convenient and effective treatment option that reduces daily intervention frequency, enhances adherence, minimizes side effects like hypoglycemia, and supports overall health management tailored to older patients. For example, in July 2024, the UK Parliament’s House of Commons Library reported that in 2022, 12.7 million people in the UK were aged 65 or older (19% of the population), projected to rise to 22.1 million (27%) by 2072. Therefore, the expanding geriatric population is driving growth in the Xultophy 100/3.6 market.
Major companies operating in the xultophy 100/3.6 market are Novo Nordisk A/S.
North America was the largest region in the xultophy 100/3.6 market in 2025. The regions covered in the xultophy 100/3.6 market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the xultophy 100/3.6 market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.
Tariffs are impacting the xultophy 100/3.6 market by increasing costs of imported active pharmaceutical ingredients, injectable device components, cold-chain logistics, and sterile packaging materials. North America and Europe are most affected due to dependence on global insulin and GLP-1 supply chains, while Asia-Pacific faces higher import-related costs. These tariffs contribute to increased manufacturing and distribution expenses that may influence pricing and reimbursement. However, they are also encouraging regional production of injectable therapies, localized device assembly, and strengthened domestic pharmaceutical supply chains.
The xultophy 100/3.6 market research report is one of a series of new reports that provides xultophy 100/3.6 market statistics, including xultophy 100/3.6 industry global market size, regional shares, competitors with a xultophy 100/3.6 market share, detailed xultophy 100/3.6 market segments, market trends and opportunities, and any further data you may need to thrive in the xultophy 100/3.6 industry. This xultophy 100/3.6 market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Xultophy 100/3.6 is a combination injectable medication containing 100 units/mL of insulin degludec and 3.6 mg/mL of liraglutide. It is used to manage type 2 diabetes mellitus (T2DM) by improving glycemic control alongside diet and exercise, addressing both insulin deficiency and GLP-1 receptor activity with a convenient once-daily injection.
The main indication for Xultophy 100/3.6 is type 2 diabetes mellitus, a chronic condition in which the body either resists insulin or the pancreas does not produce enough insulin to maintain normal blood glucose levels. It is distributed through hospital pharmacies, retail pharmacies, and online pharmacies, and is used by adult and geriatric patients.
The xultophy 100/3.6 market consists of sales of the prefilled pen for subcutaneous injection and needles. Values in this market are ‘factory gate’ values, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
Table of Contents
1. Executive Summary
2. Xultophy 100/3.6 Market Characteristics
3. Xultophy 100/3.6 Market Supply Chain Analysis
4. Global Xultophy 100/3.6 Market Trends and Strategies
5. Xultophy 100/3.6 Market Analysis of End Use Industries
7. Global Xultophy 100/3.6 Strategic Analysis Framework, Current Market Size, Market Comparisons and Growth Rate Analysis
8. Global Xultophy 100/3.6 Total Addressable Market (TAM) Analysis for the Market
9. Xultophy 100/3.6 Market Segmentation
10. Xultophy 100/3.6 Market Regional and Country Analysis
11. Asia-Pacific Xultophy 100/3.6 Market
12. China Xultophy 100/3.6 Market
13. India Xultophy 100/3.6 Market
14. Japan Xultophy 100/3.6 Market
15. Australia Xultophy 100/3.6 Market
16. South Korea Xultophy 100/3.6 Market
17. Western Europe Xultophy 100/3.6 Market
18. UK Xultophy 100/3.6 Market
19. Germany Xultophy 100/3.6 Market
20. France Xultophy 100/3.6 Market
21. Eastern Europe Xultophy 100/3.6 Market
22. North America Xultophy 100/3.6 Market
23. USA Xultophy 100/3.6 Market
24. Canada Xultophy 100/3.6 Market
25. South America Xultophy 100/3.6 Market
26. Middle East Xultophy 100/3.6 Market
27. Africa Xultophy 100/3.6 Market
29. Xultophy 100/3.6 Market Competitive Landscape and Company Profiles
32. Xultophy 100/3.6 Market High Potential Countries, Segments and Strategies
33. Appendix
Executive Summary
Xultophy 100/3.6 Market Global Report 2026 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses xultophy 100/3.6 market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
- Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on end user analysis.
- Benchmark performance against key competitors based on market share, innovation, and brand strength.
- Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
- Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for xultophy 100/3.6? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The xultophy 100/3.6 market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
- The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
- The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
- The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
- The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
- The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
- Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.
Report Scope
Markets Covered:
1) By Indication: Type 2 Diabetes Mellitus; Others2) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
3) By End User: Adult; Geriatric
Companies Mentioned: Novo Nordisk A/S
Countries: Australia; India; China; South Korea; Japan; UK; France; Germany; USA; Canada.
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: Word, PDF or Interactive Report + Excel Dashboard
Added Benefits:
- Bi-Annual Data Update
- Customisation
- Expert Consultant Support
Companies Mentioned
The companies featured in this Xultophy 100/3.6 market report include:- Novo Nordisk A/S
